开源证券股份有限公司 关于江苏四环生物股份有限公司 详式权益变动报告书 2025年第二季度持续督导意见 财务顾问 二零二五年九月 声明 开源证券股份有限公司(以下简称"开源证券"或"本财务顾问")接受碧水 农业投资的委托，担任碧水农业投资本次权益变动的财务顾问。2025年1月23日， 上市公司公告了《江苏四环生物股份有限公司详式权益变动报告书》。根据《上 市公司收购管理办法》，本财务顾问持续督导期为2025年1月23日至收购完成后12 个月。 四环生物于2025年8月27日披露了《2025年半年度报告》。通过日常沟通并结 合上市公司2025年半年度报告、其他定期公告和临时公告，本财务顾问出具本持 续督导期的持续督导意见。 作为本次权益变动的财务顾问,开源证券出具的持续督导意见是在假设本次 权益变动的各方当事人均按照相关协议条款和承诺全面行其所有职责的基础上提 出的。本财务顾问特作如下声明： 之 (一)本意见所依据的文件、资料及其他相关材料基于的假设前提是上述资料 和意见真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏；本财务顾 问未对上述资料和意见作出任何承诺或保证。 (二)本意见不构成对四环生物的任何 ...

从资金流向上来看，当日生物制品板块主力资金净流出4.46亿元，游资资金净流入1.54亿元，散户资金 净流入2.92亿元。生物制品板块个股资金流向见下表： 证券之星消息，9月3日生物制品板块较上一交易日下跌0.64%，赛升药业领跌。当日上证指数报收于 3813.56，下跌1.16%。深证成指报收于12472.0，下跌0.65%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301080 | 百普赛斯 | 65.50 | 12.10% | 5.65万 | | 3.52亿 | | 836547 | 元揚晶海 | 32.95 | 9.14% | 7.87万 | | 2.47亿 | | 600211 | 西藏药业 | 49.79 | 5.98% | 24.62万 | | 12.38亿 | | 301047 | 义翘神州 | 82.91 | 4.91% | 5.41万 | | 4.44亿 | | 688488 | 艾迪药业 | 17.20 | 3.18% | ...

Core Viewpoint - The A-share market shows a mixed performance with the Shanghai Composite Index closing above the six-month moving average, indicating potential bullish sentiment among investors [1] Group 1: Market Overview - As of 13:59 today, the Shanghai Composite Index stands at 3814.20 points, with a decline of 1.14% [1] - The total trading volume in the A-share market reached 1,878.28 billion yuan [1] Group 2: Stocks Breaking the Six-Month Moving Average - Thirteen A-shares have surpassed the six-month moving average today, with notable stocks including Renfu Pharmaceutical, Guofeng New Materials, and Zhizheng Co., which have deviation rates of 8.65%, 4.92%, and 4.08% respectively [1] - Stocks with smaller deviation rates that have just crossed the six-month moving average include Jinbo Biological, ST Huawen, and *ST Zhongzhuang [1] Group 3: Individual Stock Performance - Renfu Pharmaceutical (600079) experienced a price increase of 9.99% with a turnover rate of 8.87%, closing at 22.57 yuan, showing a deviation rate of 8.65% from the six-month moving average [1] - Guofeng New Materials (000859) rose by 6.13% with a turnover rate of 9.75%, closing at 7.10 yuan, reflecting a deviation rate of 4.92% [1] - Zhizheng Co. (603991) saw a 4.74% increase with a turnover rate of 4.15%, closing at 63.48 yuan, with a deviation rate of 4.08% [1]

| 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 半年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 600079 | 人福医 | 9.99 | 7.60 | 20.77 | 22.57 | 8.65 | | | 药 | | | | | | | 000859 | 国风新 | 8.22 | 8.12 | 6.77 | 7.24 | 6.97 | | | 材 | | | | | | | 000518 | *ST四环 | 3.46 | 2.24 | 2.31 | 2.39 | 3.30 | | 920167 | 同享科 | 1.12 | 4.87 | 20.67 | 20.84 | 0.82 | | | 技 | | | | | | | 688596 | 正帆科 | 4.01 | 3.71 | 36.31 | 36.61 | 0.81 | | | 技 | | | | | | | 688038 | 中科通 | 1.02 | 2.49 | 15.80 | 1 ...

Core Viewpoint - *ST SiHuan reported a significant increase in revenue and a reduction in losses for the first half of 2025, indicating improved operational performance despite ongoing challenges in profitability [1][3]. Financial Performance Summary - Total revenue for the first half of 2025 reached 182 million yuan, a year-on-year increase of 71.91% compared to 106 million yuan in 2024 [1]. - The net profit attributable to shareholders was -10.1 million yuan, showing an 8.67% improvement from -11.1 million yuan in the previous year [1]. - In Q2 2025, total revenue was 138 million yuan, up 179.41% year-on-year, with a net profit of 5.8 million yuan, an increase of 171.88% [1]. Key Financial Metrics - Gross margin decreased to 34.69%, down 48.08% year-on-year, while net margin improved to -5.71%, an increase of 48.08% [1]. - Total expenses (selling, administrative, and financial) amounted to 65.3 million yuan, accounting for 35.92% of revenue, a decrease of 41.98% year-on-year [1]. - Cash flow from operating activities per share increased significantly to 0.05 yuan, a rise of 60666.79% year-on-year [1]. Changes in Financial Items - Cash and cash equivalents increased by 506.4% due to increased sales from strategic partnerships [3]. - Inventory decreased by 22.97% as a result of reduced stock from sales [3]. - Operating income rose by 71.91% attributed to increased sales from strategic collaborations [3]. Business Evaluation - The company's historical return on invested capital (ROIC) has been poor, with a median of -4.56% over the past decade, and a particularly low -22.43% in 2024 [4]. - The business model relies heavily on marketing-driven performance, necessitating further investigation into the underlying drivers of this performance [4]. Cash Flow and Financial Health - The cash flow situation is concerning, with cash and cash equivalents representing only 9.3% of total assets and 92.91% of current liabilities [5]. - Financial expenses have reached 77.86% of the average operating cash flow over the past three years, indicating potential financial strain [5]. - Inventory levels are high, with inventory accounting for 136.22% of revenue, suggesting inefficiencies in inventory management [5].

Core Viewpoint - *ST SiHuan reported a significant increase in revenue and a narrowing of losses in its 2025 mid-year report, indicating improved operational performance despite ongoing challenges [1][3]. Financial Performance - The total operating revenue reached 182 million yuan, a year-on-year increase of 71.91% [1] - The net profit attributable to shareholders was -10.1 million yuan, showing an 8.67% improvement compared to the previous year [1] - In Q2, the operating revenue was 138 million yuan, up 179.41% year-on-year, with a net profit of 5.82 million yuan, an increase of 171.88% [1] Key Financial Metrics - Gross margin was 34.69%, down 48.08% year-on-year [1] - Net margin improved to -5.71%, an increase of 48.08% year-on-year [1] - Total expenses (selling, administrative, and financial) amounted to 65.34 million yuan, accounting for 35.92% of revenue, a decrease of 41.98% year-on-year [1] - Earnings per share remained at -0.01 yuan, with a year-on-year increase of 8.41% [1] Cash Flow and Assets - Cash and cash equivalents increased by 340.20% to 48.59 million yuan due to increased sales from strategic partnerships [3] - Operating cash flow per share improved significantly to 0.05 yuan, a year-on-year increase of 60666.79% [1][3] - The company’s receivables decreased slightly by 1.36% to 67.31 million yuan [1] Strategic Developments - The increase in revenue and cash flow is attributed to a strategic partnership with Jiangyin Xinganfa Trading Co., leading to higher sales of seedlings [3] - The company reduced its inventory by 22.97% as a result of increased sales [3] Financial Health Indicators - The company’s financial leverage improved, with interest-bearing debt decreasing by 70.88% to 6.13 million yuan [1] - The ratio of financial expenses to average operating cash flow over the past three years reached 77.86%, indicating a high burden of financial costs [5] - Inventory levels are concerning, with inventory to revenue ratio at 136.22% [5]

Market Overview - The biopharmaceutical sector experienced a decline of 2.85% on August 27, with Kanghua Biotech leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Wuwei Biotech (300357) saw a significant increase of 5.38%, closing at 30.95 with a trading volume of 299,000 shares and a transaction value of 915 million yuan [1] - Kanghua Biotech (300841) reported a notable decline of 8.89%, closing at 76.60 with a trading volume of 125,200 shares and a transaction value of 993 million yuan [2] - Anke Biotech (300009) also faced a drop of 5.59%, closing at 11.14 with a trading volume of 862,300 shares and a transaction value of 990 million yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 1.853 billion yuan from institutional investors, while retail investors saw a net inflow of 1.543 billion yuan [2] - The capital flow for individual stocks indicates that Hualan Biotech (002007) had a net inflow of 32.28 million yuan from institutional investors, while it faced a net outflow of 40.67 million yuan from speculative funds [3] - The overall trend shows that retail investors are actively investing in the sector despite the institutional outflows [2][3]

Core Insights - *ST SiHuan reported a total revenue of 182 million yuan as of June 30, 2025, ranking 27th among disclosed peers [1] - The company recorded a net profit attributable to shareholders of -10.1 million yuan, ranking 23rd among disclosed peers [1] - Operating cash flow was positive at 50.2 million yuan as of June 30, 2025 [1] Financial Performance - The asset-liability ratio stood at 25.80%, ranking 21st among disclosed peers, an increase of 3.08 percentage points compared to the same period last year [3] - Gross margin was reported at 34.69%, ranking 30th among disclosed peers, a decrease of 29.70 percentage points from the previous quarter and 32.13 percentage points year-on-year [3] - Return on equity (ROE) was -2.79%, ranking 27th among disclosed peers, a decline of 0.44 percentage points from the previous year [3] Earnings and Ratios - The diluted earnings per share were -0.01 yuan, ranking 22nd among disclosed peers [4] - Total asset turnover was 0.33 times as of June 30, 2025 [4] - Inventory turnover ratio was 0.37 times, ranking 22nd among disclosed peers [4] Shareholder Structure - The number of shareholders was 73,300, with the top ten shareholders holding 458 million shares, accounting for 44.44% of total equity [4] - The largest shareholder, Fujian Bihui Agricultural Investment Co., Ltd., holds 27.78% of the shares [4]

每经AI快讯，*ST四环（SZ 000518，收盘价：2.47元）8月27日发布半年度业绩报告称，2025年上半年 营业收入约1.82亿元，同比增加71.91%；归属于上市公司股东的净利润亏损约1010万元；基本每股收益 亏损0.0098元。2024年同期营业收入约1.06亿元；归属于上市公司股东的净利润亏损约1106万元；基本 每股收益亏损0.0107元。 每经头条（nbdtoutiao）——能给主人"打电话"的宠物智能手机也来了！宠物产业3000亿元市场大爆 发，行业上市公司"涨"声一片 （记者 王晓波） ...

Group 1 - The company Jiangsu Sihuan Biological Co., Ltd. announced a capital reduction of 150 million yuan for its wholly-owned subsidiary Jiangsu Chenwei Ecological Park Technology Co., Ltd., reducing its registered capital from 400 million yuan to 250 million yuan [1][3] - The decision for the capital reduction was approved during the 16th meeting of the 10th board of directors held on August 25, 2025, and does not constitute a related party transaction or a major asset restructuring, thus not requiring shareholder approval [1][2] - The capital reduction aims to enhance asset management efficiency in line with the company's medium to long-term strategic planning, and it will not adversely affect the company's financial status or operating results [3] Group 2 - Jiangsu Chenwei Ecological Park Technology Co., Ltd. has total assets of approximately 305.86 million yuan and total liabilities of about 72.76 million yuan as of the first half of 2025 [2] - The company reported a net profit of -2.47 million yuan for the first half of 2025, compared to a net profit of -70.31 million yuan for the entire year of 2024 [2] - The subsidiary is not listed as a dishonest executor, indicating a stable legal standing [2]